# Chemotherapy for Gastric Cancer Is Not Solely the Domain of the Oncologist

## TL;DR

Chemotherapy for gastric cancer should involve a multidisciplinary team, not just oncologists, to better manage side effects and improve patient outcomes.

## Contribution

The paper advocates for internal medicine departments to lead chemotherapy administration in collaboration with oncologists and gastroenterologists.

## Key findings

- Chemotherapy's adverse effects often outweigh its benefits, necessitating a multidisciplinary approach.
- Immunosuppression from chemotherapy increases infection risk and complicates treatment.
- Limited access to supportive therapies like rehydration infusions affects patient recovery and treatment outcomes.

## Abstract

In the context of gastric cancer, chemotherapy is frequently employed as a systemic treatment, particularly when curative options are limited or not feasible. Patients diagnosed with cancer often seek to extend survival and may place considerable hope in chemotherapy as a key therapeutic avenue. The efficacy of chemotherapy depends on adequate recovery between treatment cycles, with the patient’s hematologic and systemic recovery status serving as key determinants of tolerance to subsequent doses and of overall treatment outcome. The administration of chemotherapy regimens frequently results in immunosuppression, and this compromised immune state elevates patients’ susceptibility to opportunistic infections, with implications for infection prevention and management. During intervals between chemotherapy cycles, access to rehydration infusions that provide vitamins B1, B6, and C is frequently limited, and payment for these adjunctive therapies is commonly borne by patients. Given the significance of the issue, urgent engagement by the medical community appears warranted; this article presents a potential solution.

Adverse effects of chemotherapeutic agents remain a significant clinical challenge in the management of gastric cancer. Across the literature, discussions of chemotherapy consistently document a range of toxicities, underscoring that even when treatment halts disease progression, it can leave substantial clinical sequelae. Chemotherapy can impact virtually every organ system, producing multiorgan toxicity with meaningful implications for patient quality of life and treatment feasibility. When initiating a new chemotherapy regimen, prior lack of therapeutic benefit is often associated with difficult recovery or inability to tolerate subsequent chemotherapy, thereby constraining future therapeutic options. Given these considerations and the current absence of universally personalized treatment, a multidisciplinary team—comprising a medical oncologist, gastroenterologist, and internist—is essential to the planning and execution of chemotherapy regimens. We recommend that these chemotherapy regimens be administered within internal medicine departments, in collaboration with the medical oncologist and gastroenterologist, because in many cases the adverse effects outweigh the potential benefits of chemotherapy.